Defence Therapeutics Inc.
- ISIN: CA24463V1013
- Land: Canada
Nachricht vom 06.10.2021 | 08:30
Defence Therapeutics Inc.: DEFENCE THERAPEUTICS PREPARES FOR PHASE I TRIAL TO TEST ITS DC CANCER VACCINE, ACCUVAC-D002, AGAINST MELANOMA
DGAP-News: Defence Therapeutics Inc.
/ Key word(s): Miscellaneous
CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE
DEFENCE THERAPEUTICS PREPARES FOR PHASE I TRIAL TO TEST ITS DC CANCER VACCINE, ACCUVAC-D002, AGAINST MELANOMA
Vancouver, BC, Canada, October 6th, 2021 - Defence Therapeutics Inc. ("Defence" or the "Company"), a biotechnology company working on cancer therapeutics and infectious disease vaccines is finalizing all required steps in preparation to a pre-IND meeting to initiate a phase I trial against melanoma using its DC cancer vaccine candidate AccuVAC-D002.
Defence has successfully exploited the use of its AccumTM technology platform to develop a large pipeline of products in immune-oncology and infectious diseases. Amongst its lead products is AccuVAC-D002, a DC-based cancer vaccine engineered to treat melanoma. The AccumTM technology platform is very efficient at enhancing intracellular delivery of proteins of pharmacological interests such as ADCs or vaccine antigens. Defence's scientific team recently identified a novel function for the use of "free" AccumTM and its recently developed variants as anti-cancer molecules.
Defence Therapeutics has antibody-drug conjugates and vaccines in late-stage pre-clinical development and/or undergoing GLP studies. With two DC cancer vaccines (AccuVAC-D001 and D002) undergoing manufacturing in clean rooms, Defence is most likely to initiate its Phase I trials in Q1/Q2 of 2022.
Skin Cancer Treatment Market to reach USD 14.55 Billion with a 7.5% CAGR by 2027, according to a report by Fortune Business InsightsTM.
For further information:
|Company:||Defence Therapeutics Inc.|
|1680 - 200 Burrard St|
|Listed:||Regulated Unofficial Market in Frankfurt, Stuttgart; Toronto|
|EQS News ID:||1238582|
|End of News||DGAP News Service|
Defence Therapeutics Inc.: EINLEITUNG DER HERS ...
DEFENCE THERAPEUTICS CANCER VACCINE ACCUVAC-D0 ...
Defence Therapeutics Inc.: DEFENCE THERAPEUTIC ...
DEFENCE THERAPEUTICS APPOINTS DR. RIAM SHAMMAA ...
VACCINE RESULTS: DEFENCE THERAPEUTICS REPORTS ...
GBC im Fokus
IGEA Pharma N.V. Realignment to CBD extraction
The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.
Der AKTIONÄR News
29. November 17:10 DAX: Das war mau
29. November 17:15 Alibaba dringt ins Tencent-Universum ein
29. November 18:00 Bitcoin mit Verlusten: Ist das die Einstiegschance? Hier kommt die ...
29. November 18:00 Nur noch heute: Profitieren Sie von den Black Friday Megadeals!
29. November 18:29 Ölpreise erholt nach "kompletter Überreaktion" - BP, Exxon & Co im ...
Original-Research: Gold Mountain Mining Corp. (von hanseatic stock publishing UG (haftungsbeschränkt)): Gold Mountain Mining Corp.
29. November 2021